Annexon, Inc. (ANNX) DCF Valuation

Annexon, Inc. (ANNX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Annexon, Inc. (ANNX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Engineered for accuracy, our [ANNX] DCF Calculator enables you to evaluate Annexon, Inc. valuation using real-world financial information and provides complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -32.0 -62.8 -128.6 -143.5 -141.6 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .5 .7 3.4 3.3 2.1 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -32.5 -63.5 -132.0 -146.8 -143.7 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 43.9 351.2 242.7 242.7 259.7 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .1 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.4 3.7 11.2 7.4 5.5 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -.3 -.5 -1.7 -6.5 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -32.5 -62.8 -129.4 -143.0 -143.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -30.0 -61.2 -120.2 -150.0 -143.7 -5.5 .0 .0 .0 .0
WACC, % 9.83 9.82 9.82 9.82 9.83 9.82 9.82 9.82 9.82 9.82
PV UFCF
SUM PV UFCF -5.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -5
Net Debt -194
Equity Value 189
Diluted Shares Outstanding, MM 76
Equity Value Per Share 2.49

What You Will Receive

  • Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled real ANNX financials.
  • Accurate Data: Historical figures and forward-looking projections (as indicated in the highlighted cells).
  • Flexible Forecasting: Modify forecast parameters such as revenue growth, EBITDA %, and WACC.
  • Instant Calculations: Quickly observe how your inputs affect Annexon’s valuation.
  • Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
  • Intuitive Layout: Organized for clarity and ease of use, complete with step-by-step guidance.

Key Features

  • 🔍 Real-Life ANNX Financials: Pre-filled historical and projected data for Annexon, Inc. (ANNX).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Annexon’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Annexon’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Download: Get the pre-configured Excel file featuring Annexon, Inc.'s (ANNX) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Generate various forecasts and compare results instantly.
  • Make Decisions: Leverage the valuation outcomes to inform your investment approach.

Why Choose Annexon, Inc. (ANNX)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of experienced professionals with a strong track record in neuroscience.
  • Robust Pipeline: A diverse range of candidates in various stages of development.
  • Commitment to Patients: Focused on improving the lives of those affected by neurodegenerative diseases.
  • Strong Partnerships: Collaborations with leading research institutions and organizations enhance our capabilities.

Who Should Use This Product?

  • Investors: Accurately estimate Annexon, Inc.'s (ANNX) fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Annexon, Inc. (ANNX).
  • Consultants: Efficiently customize the template for valuation reports tailored to Annexon, Inc. (ANNX) clients.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Annexon, Inc. (ANNX).
  • Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to Annexon, Inc. (ANNX).

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Annexon, Inc. (ANNX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Annexon, Inc. (ANNX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.